The investment in Fujifilm Diosynth Biotechnologies will expand production lines for bulk drug substances and cultivate cells for producing viral vaccines, Fujifilm announced on Tuesday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback